Allogene Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Nov 2017 | — | $0 | $0 |
| Dec 2017 | — | $-2.0K | $0 |
| Mar 2018 | — | $-2.6M | $5.0K |
| Jun 2018 | — | $-129.4M | $143.9M |
| Sep 2018 | — | $-168.4M | $83.1M |
| Dec 2018 | — | $703.2M | $92.4M |
| Mar 2019 | — | $681.2M | $92.7M |
| Jun 2019 | — | $655.6M | $112.6M |
| Sep 2019 | — | $619.7M | $161.0M |
| Dec 2019 | — | $629.0M | $175.1M |
| Mar 2020 | — | $606.5M | $135.9M |
| Jun 2020 | — | $1.16B | $280.4M |
| Sep 2020 | — | $1.12B | $158.1M |
| Dec 2020 | — | $1.01B | $183.4M |
| Mar 2021 | — | $1.07B | $236.9M |
| Jun 2021 | — | $1.02B | $223.5M |
| Sep 2021 | — | $969.9M | $190.0M |
| Dec 2021 | — | $925.2M | $173.3M |
| Mar 2022 | — | $865.3M | $84.5M |
| Jun 2022 | — | $806.5M | $96.0M |
| Sep 2022 | — | $743.4M | $74.4M |
| Dec 2022 | — | $666.9M | $61.9M |
| Mar 2023 | — | $592.0M | $109.9M |
| Jun 2023 | — | $621.4M | $154.8M |
| Sep 2023 | — | $580.6M | $69.2M |
| Dec 2023 | — | $512.2M | $83.2M |
| Mar 2024 | — | $461.4M | $51.0M |
| Jun 2024 | — | $515.0M | $170.7M |
| Sep 2024 | — | $463.7M | $51.2M |
| Dec 2024 | — | $422.2M | $75.2M |
| Mar 2025 | — | $385.4M | $42.5M |
| Jun 2025 | — | $344.6M | $52.3M |
| Sep 2025 | — | $315.3M | $37.8M |
| Dec 2025 | — | $292.5M | $51.7M |
| Mar 2026 | — | $278.9M | $30.3M |
| Jun 2026 | — | $436.2M | $38.6M |